Six of them, namely LTBP1, COX4I2, CYP19A1, F2RL2, MECP2, and S1PR3, demonstrated notable upregulation in CRC samples, while the remaining four genes, HLF, HDC, SLC18A2, and GPR162, exhibited comparatively lower expression. This evidence concerns the gene GPR162 and colorectal carcinoma.